InNexus Biotechnology Inc. - Strategic Analysis Review
Summary
InNexus Biotechnology Inc. is a development stage biotechnology company focused on the development of the next generation of monoclonal antibodies using its Dynamic Cross-linking (DXL) technology. The DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effect or functions and installing new properties into antibodies.
This report presents an in-depth strategic and operational analysis of InNexus Biotechnology Inc.. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis on the company.
Scope
-The company's strengths and weaknesses and areas of development or decline are analyzed. Strategic and operational factors are considered.
-The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
-The report contains critical company information - business structure and operations, company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
Reasons to buy
-A quick "one-stop-shop" to understand the company.
-Enhance business/sales activities by understanding customers' businesses better.
-Get detailed information and strategic analysis on companies operating in your industry.
-Identify prospective partners and suppliers - with key data on their businesses and locations.
-Capitalize on competitors' weaknesses and target the market opportunities available to them.
-Scout for potential acquisition targets, with detailed insight into the companies' strategic and operational performance.
http://www.companiesandmarkets.com/link.asp?id=RR4BJ4I7Y72347
CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 7813 784 393 Fax: +44 1536 790 144 e-mail: info@companiesandmarkets.com WWW: http://www.companiesandmarkets.com/link.asp?id=RR4BJ4I7Y72347
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index